BPOM Permits The Use Of AstraZeneca Batch CTMAV547 Vaccine Again Even Though There Are Death Cases

PT Bank Central Asia Tbk (BCA) has started implementing Mutual Cooperation vaccinations for its employees. (Photo: Doc. BCA)

JAKARTA - The Food and Drug Supervisory Agency (BPOM) has finished testing the quality of the AstraZeneca vaccine batch CTMAV547.

This batch was discontinued due to a case of death after receiving the injection of the AstraZeneca batch.

The National Food and Drug Testing Development Center (PPPOMN) BPOM published the AstraZeneca COVID-19 vaccine Testing Report batch CTMAV547. In conclusion, the abnormal toxicity and sterility of CTMAV547 batch meet the quality requirements and are safe to use.

Thus, the Head of BPOM Penny K. Lukito said there was no link between the quality of the Astrazeneca COVID-19 vaccine batch number CTMAV547 and the post-immunization follow-up incident (KIPI) of the death case.

"For this reason, AstraZeneca's COVID-19 vaccine batch number CTMAV547 can be reused," said Penny in a statement, Thursday, May 28.

Penny said, BPOM will continue to supervise the quality of the COVID-19 vaccine before it is distributed by issuing lot releases to circulation, by taking periodic samples and quality testing.

"The POM Agency together with the Ministry of Health of the Republic of Indonesia and Komnas PP KIPI continue to monitor the safety of vaccines used in Indonesia and follow up on each AEFI," he said.

As is known, a 22 year old youth from Buaran, East Jakarta, named Trio Fauqi Virdaus died after being injected with the AstraZeneca vaccine the day before.

Initially, Trio felt symptoms of fever after receiving the AstraZeneca vaccine injection at Istora Senayan on Wednesday, May 5.

The next day, the Trio's condition weakened. He was then taken to the hospital. However, the Trio's lives could not be saved. Trio was declared dead on Thursday, May 6 at around 12.30 WIB.

Finally, the Ministry of Health temporarily stopped the use of a production batch or batch of the AstraZenexa vaccine with the CTMAV547 type. This was followed by a young man who died after being vaccinated with AstraZeneca type CTMAV547.